Anti-PD-(L)1 and anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies enhance anti-tumor immune responses through different phases and mechanisms [10]. This evidence concerns the gene CTLA4 and neoplasm.